National surgical adjuvant breast and bowel project study of tamoxifen and raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities

Clinical Trials

Volumn 10, Issue 2, 2013, Pages 280-291

  McCaskill Stevens, Worta ^a,b   Wilson, John W ^b,c   Cook, Elise D ^d   Edwards, Cora L ^e   Gibson, Regina V ^f   McElwain, Diane L ^g   Figueroa Moseley, Colmar D ^h   Paskett, Electra D ⁱ   Roberson, Noma L ^j   Wickerham, D Lawrence ^b,k   Wolmark, Norman ^b,k  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NSABP Foundation Inc   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g York Cancer Center   (United States)

^h California Tobacco Control Program   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j Roberson Consulting International   (United States)

^k ALLEGHENY GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CAUCASIAN; DRUG EFFICACY; ETHNIC GROUP; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION;

AFRICAN AMERICANS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOPREVENTION; COMMUNITY-BASED PARTICIPATORY RESEARCH; CONTINENTAL POPULATION GROUPS; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TAMOXIFEN;

EID: 84876590452     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512470315     Document Type: Article

References (21)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 ; 90: 1371-88
2. American Cancer Society. Cancer Facts & Figures for African Americans 2009-2010. American Cancer Society, Atlanta, GA, 2009. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/ f861009final90809pdf.pdf (accessed 13 October 2011).
3. HowladerNNooneAMKrapchoM. (eds). SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD, 2011. Available at: http://seer.cancer.gov/csr/1975-2008/ (based on November 2010 SEER data submission, posted to the SEER web site) (accessed 17 October 2011).
4. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review. Cancer. 2008 ; 112: 228-42
5. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 ; 295: 2727-41
6. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989 ; 81: 1879-86
7. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999 ; 91: 1829-1846
8. Vital Statistics of the United States, 1992, vol. II, Mortality, Part A. Washington, DC: Public Health Service ; 1996 :
9. http://seer.gov/data (accessed 13 October 2011).
10. http://www.cancer.gov/bcrisktool/ (accessed 13 October 2011).
11. McCaskill-Stevens W, Wilson J, Bryant J, et al. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. J Natl Cancer Inst. 2004 ; 96: 1762-69
12. Boesch M. Nana's Lesson. National Indian Child Welfare Association's Best Practices Magazine. Portland, OR: National Indian Child Welfare Association (NICWA) ; 2001 :
13. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003 ; 95: 526-32
14. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999 ; 30: 736-43
15. Kittner SJ, White LR, Losonezy KG, Wolf PA, Hebel JR.. Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. JAMA. 1990 ; 264: 1267-70
16. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 ; 301: 39-51
17. Cook ED, Moody-Thomas S, Anderson KB, et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clin Trials. 2005 ; 2: 436-42
18. Spilker B, Cramer J. Patient Recruitment in Clinical Trials. New York: Raven Press ; 1992: 83-86.
19. Grann VR, Jacobson JS, Troxel AB, et al. Barriers to minority participation in breast carcinoma prevention trials. Cancer. 2005 ; 104: 374-79
20. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007 ; 99: 1782-92
21. Adams-Campbell LL, Makambi KH, Frederick WA, et al. Breast cancer risk assessment comparing Gail and CARE Models in African-American women. Breast J. 2009 ; 15: S72 - S75